Cannabinoid therapeutic - ZYUS Life Sciences
Alternative Names: Trichomylin®Latest Information Update: 01 Aug 2024
At a glance
- Originator ZYUS Life Sciences
- Class Analgesics; Cannabinoids
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Pain
Most Recent Events
- 31 Jul 2024 ZYUS Life Sciences Corporation received a no objection letter (NOL) from Health Canada for a proof-of-concept trial for Trichomylin® softgel capsules
- 04 Jun 2024 Trichomylin is still in phase I trial for Pain (In volunteers) in Australia (PO) (NCT04867057)
- 04 Jun 2024 ZYUS Life Sciences plans a phase II trial in Pain in Canada (PO) in 2024